Skip to main content
NVZMY logo

Novozymes A/S (NVZMY) Stock Price & Analysis

Novozymes A/S (NVZMY) — price $66.01 (-0.29%), as of the Nov 18, 2026 trading session; market cap $30.8B.

Educational signal · not a buy or sell recommendation · How to read this

$66.01 −$0.19 (-0.29%) Market Cap $30.8B

Novozymes A/S · NVZMY · Basic Materials · Chemicals - Specialty

Novozymes A/S is a global biotechnology firm that specializes in the creation and distribution of industrial enzymes, microorganisms, and probiotics.

Price as of Nov 18, 2026

Key Statistics

No MoonshotScore yet: we have not published a score for this company.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • PPG · PPG Industries, Inc. · 79 /100
  • IFF · International Flavors & Fragrances Inc. · 56 /100
  • DD · DuPont de Nemours, Inc. · 43 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$66.01
Change on the day-0.29%
52-week range$49.90–$75.27
Market capitalisation$30.8B—
Price / earnings (trailing)40.26
Shares traded on the day2.9K
Beta (volatility vs the S&P 500)0.62

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 18, 2026: low $54, high $72, latest $66. $72 $54 high $72 Oct 17, 2025 Nov 18, 2026 · $66 $64Oct 17, 2025$60Oct 31, 2025$64Nov 14, 2025$62Nov 28, 2025$62Dec 12, 2025$64Dec 26, 2025$66Jan 9, 2026$64Jan 23, 2026$61Feb 6, 2026$61Feb 20, 2026$57Mar 6, 2026$54Mar 20, 2026$60Apr 2, 2026$60Apr 17, 2026$62May 1, 2026$59May 15, 2026$58May 29, 2026$60Jun 12, 2026$62Jun 26, 2026$65Jul 10, 2026$62Jul 24, 2026$66Aug 7, 2026$70Aug 21, 2026$68Sep 4, 2026$66Sep 18, 2026$63Oct 2, 2026$68Oct 16, 2026$69Oct 30, 2026$68Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for Novozymes A/S (NVZMY): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

6 lenses, 6 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Unfavorable read
Simons-style lens (simulated) Jim Simons Favorable read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Favorable read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Moderate
Margin of Safety Fairly Valued
Profit Margin Moderate
Revenue Growth Strong
Debt/Equity Moderate
ROE Neutral
Gross Margin Moderate

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Novozymes A/S (NVZMY), and what does it report?

Short answer

Novozymes A/S is a global biotechnology firm that specializes in the creation and distribution of industrial enzymes, microorganisms, and probiotics. Basic Materials / Chemicals Specialty SEC filing business address: Krogsho Jvej 36 2880 Bagsverd, Gladsaxe Denmark, G7, 00000. It employs 11,641 people and is led by Ester Baiget. The market values it at $30.8B.

3 · Financial strengths and risks

What are the financial strengths and risks for Novozymes A/S (NVZMY)?

Short answer · as of

The distress and quality screens read Altman Z 23.95 · Piotroski F 5. Trailing ratios: ROE 6.2% · ROA 4.0% · current ratio 1.53 · earnings yield 2.4% · free-cash-flow yield 2.8%.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held NVZMY in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported NVZMY in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Novozymes A/S (NVZMY)?

Read these with our analysis →

Common Questions About NVZMY (Basic Materials)

Research dated 2026-09-12; the full attribution is under Sources. The last question is answered from this page's own dated data, not from the research.

What does Novozymes sell to food and beverage producers?

It supplies ingredients and processing aids used in baking, beverages, dairy production, starch modification and protein applications. Management expects this business to lead the company’s organic sales growth.

Why do high comparables matter for Novozymes?

A demanding comparison base raises the hurdle for reported growth even when current demand remains constructive. Management has explicitly flagged that pressure alongside its margin outlook.

What is the NVZMY stock price today?

The last price recorded for Novozymes A/S (NVZMY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 15 figures on this page — 1 from SEC filings and earnings calls, 11 from Financial Modeling Prep (FMP) and 3 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-12), by section of the research

  • FAQ: What does Novozymes sell to food and beverage producers?: Business description; Management outlook — dated call excerpts
  • FAQ: Why do high comparables matter for Novozymes?: Management outlook — dated call excerpts
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.